• Key competencies
    • The ability to quickly spot key project strengths and weaknesses.
    • The ability to identify and communicate the business impact of diverse aspects of a project (early and clinical development, safety matters, health economic and marketing plans).
    • Develop and present clear and convincing communications to convey project messages.
  • Abbreviated CV
    • 2012 - current
    • CEO, Xintera Ltd (Cambridge, UK).
    • Sep 2009 - Sep 2010
    • Chief Medical Officer, TiGenix NV (Leuven, Belgium)
    • Mar 2007 - Mar 2009
    • Chief Medical Officer, elbion NV (Leuven, Belgium)
    • Apr 2007 - Dec 2013
    • Managing Director, Xintera Consulting bvba (Leuven. Belgium)
    • Sep 2009 - Sep 2010
    • Managing Director, Xintera Consulting bvba (Leuven. Belgium)
    • Aug 2005 - Feb 2007
    • Executive Director, Clinical Research, Theratechnologies (Montreal, QC)
    • Dec 2004 - Aug 205
    • Director, Scientific Affairs and Medical Operations, Pfizer Canada (Montreal, QC)
    • Jan 2004 - Dec 2004
    • Director, Medical Operations, Pfizer Canada (Montreal, QC)
    • 2000 - 2003
    • Director, Clinical Research Operations, Pfizer Canada (Montreal, QC)
    • 1999 - 2000
    • Associate Medical Director, Pfizer Canada (Montreal, QC)
    • 1996 - 1998
    • Associate Medical Director, Trovan Global Development Team, Pfizer Inc, (New York, NY)
    • 1995 - 1996
    • Associate Medical Director, Medical Operations, Pfizer Inc, (New York, NY)
    • 1991 - 1992
    • Resident, Tropical Medicine/AIDS, Prince Leopold Institute for Tropical Medicine (Antwerp, Belgium)
    • 1987 - 1990
    • Tropical Doctor, Médecins sans Frontièwres
  • Publications
    • Blot K, Michel MC. Authors' response to Hermann et al. Minimum quality criteria are needed in the assessment and communication of unexpected drug safety findings of marketed products from RCTs. Br J Clin Pharmacol. 2012 Jul;74(1):209–10.

    • Michel M, Radziszewski P, Falconer C, Marschall-Kehrel D, Blot K. Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. Br J Clinical Pharmacol 2011 Nov 2. doi: 10.1111/j.1365-2125.2011.04138.x. [Epub ahead of print]

    • Falutz, J., et al., Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med, 2007. 357(23): p. 2359-70.

    • Blot, K. Sponsor Challenges and Threats: To ‘e’ or not to ‘e’? Perspectives 2003 Jun; 1(2):22-7.

    • Blot S, Vandewoude K, Blot K, Colardyn F. Prevalence and risk factors for colonisation with gram-negative bacteria in an intensive care unit. Acta Clin Belg. 2000 Sep-Oct;55(5):249-56.

    • Van den Ende J, Blot K, Kestens L, Van Gompel A, Van den Enden E. Kabisa: an interactive computer-assisted training program for tropical diseases. Med Educ. 1997 May;31(3):202-9.

    • Sternon J, Leclerq P, Knepper C, Blot K. Azithromycin compared with clarithromycin in the treatment of adult patients with acute purulent tracheobronchitis: a cost of illness study. J Int Med Res. 1995 Nov-Dec;23(6):413-22.

    • Colebunders R, Vael C, Blot K, Van Meerbeeck J, Van den Ende J, Ieven M. Bordetella pertussis as a cause of chronic respiratory infection in an AIDS patient. Eur J Clin Microbiol Infect Dis. 1994 Apr;13(4):313-5.

    • Colebunders R, Sow S, Blot K, Vandenbruaene M, Heerackers Y, Kestens L, Van Ham G, Cornelissen W, Blot K. HIV diagnosis delay in Antwerp, Belgium. J Epidemiol Community Health. 1994 Apr;48(2):212.

    • Colebunders R, Mertens V, Blot K, Neetens I, Van Marck E, Batungwanayo J, Taelman H. Pulmonary T-cell lymphoma in a patient with the acquired immunodeficiency syndrome. Clin Infect Dis. 1993 Jan;16(1):188.

    • Colebunders R, De Serrano P, Van Gompel A, Wynants H, Blot K, Van den Enden E, Van den Ende J. Imported relapsing fever in European tourists. Scand J Infect Dis. 1993;25(4):533-6.

    • Ramael M, Colebunders R, Colpaert C, Goeman J, Schrijvers D, Lachenal M, Vandenbruaene M, Blot K, Van Marck E. The prevalence of hairy leukoplakia in HIV seropositive and HIV seronegative immunocompromised patients. Int J STD AIDS. 1992 Jul-Aug;3(4):251-4.

    • Colebunders R, Blot K, Mertens V, Dockx P. Psoriasis regression in terminal AIDS. Lancet. 1992 May 2;339(8801):1110.

    • Colebunders R, Sow S, Coulibaly M, Blot K. Efficacy of octreotide in the management of chronic diarrhoea in AIDS. AIDS. 1992 May;6(5):512.
Open all